Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies

Trial Profile

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 Nov 2018

At a glance

  • Drugs INCAGN 1949 (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications Head and neck cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Incyte Biosciences International
  • Most Recent Events

    • 29 Oct 2018 Planned End Date changed from 1 Nov 2021 to 1 Mar 2019.
    • 29 Oct 2018 Planned primary completion date changed from 1 May 2021 to 1 Mar 2019.
    • 29 Oct 2018 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top